for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Regeneron Pharmaceuticals Inc

REGN.O

Latest Trade

508.31USD

Change

2.21(+0.44%)

Volume

712,031

Today's Range

507.18

 - 

515.47

52 Week Range

328.12

 - 

664.64

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
506.10
Open
507.18
Volume
712,031
3M AVG Volume
20.33
Today's High
515.47
Today's Low
507.18
52 Week High
664.64
52 Week Low
328.12
Shares Out (MIL)
106.71
Market Cap (MIL)
55,872.47
Forward P/E
17.20
Dividend (Yield %)
--

Next Event

Regeneron Pharmaceuticals Inc at Piper Sandler Healthcare Conference (Virtual)

Latest Developments

更多

Regeneron's Regen-Cov2 Is First Antibody Cocktail For Covid-19 To Receive FDA Emergency Use Authorization

U.S. FDA Authorizes Monoclonal Antibodies For Treatment Of COVID-19

Regeneron Reports Q3 Non-Gaap Earnings Per Share $8.36

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.

Industry

Biotechnology & Drugs

Contact Info

777 Old Saw Mill River Rd

TARRYTOWN, NY

10591-6717

United States

+1.914.8477000

https://www.regeneron.com/

Executive Leadership

P. Roy Vagelos

Chairman of the Board, Director

Leonard S. Schleifer

President, Chief Executive Officer, Director

George D. Yancopoulos

President, Chief Scientific Officer, Director

Robert E. Landry

Chief Financial Officer, Executive Vice President - Finance

Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

Key Stats

2.11 mean rating - 27 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

5.9K

2018

6.7K

2019

7.9K

2020(E)

8.5K
EPS (USD)

2017

16.320

2018

22.840

2019

24.670

2020(E)

30.263
Price To Earnings (TTM)
19.14
Price To Sales (TTM)
6.78
Price To Book (MRQ)
5.51
Price To Cash Flow (TTM)
16.51
Total Debt To Equity (MRQ)
26.61
LT Debt To Equity (MRQ)
26.61
Return on Investment (TTM)
24.35
Return on Equity (TTM)
21.02

Latest News

Latest News

UPDATE 1-U.S. to begin distributing Regeneron's COVID-19 antibody therapy Tuesday

The U.S. government will start distributing Regeneron Pharmaceuticals Inc's newly authorized COVID-19 antibody combination on Tuesday, beginning with over 30,000 treatment courses, a health official said on Monday.

U.S. to begin distributing Regeneron's COVID-19 antibody therapy starting Tuesday

U.S. government will begin distributing Regeneron Pharmaceuticals Inc's newly authorized COVID-19 antibody combination therapy starting Tuesday, beginning with over 30,000 courses, a health official said during a media call on Monday.

UPDATE 2-U.S. FDA grants emergency use authorization to Regeneron COVID-19 antibody given to Trump

The U.S. Food and Drug Administration on Saturday issued emergency use authorization for Regeneron Pharmaceuticals Inc's COVID-19 antibody therapy, an experimental treatment given to U.S. President Donald Trump that he said helped cure him of the disease.

U.S. FDA grants emergency use authorization to Regeneron COVID-19 antibody given to Trump

The U.S. Food and Drug Administration on Saturday issued an emergency use authorization for Regeneron Pharmaceuticals Inc's COVID-19 antibody therapy, an experimental treatment given to U.S. President Donald Trump that he said helped cure him of the disease.

Regeneron says Roche successfully tested manufacture of COVID-19 drug used on Trump

Roche Holding AG has completed early tests of its ability to produce large quantities of Regeneron Pharmaceuticals Inc's COVID-19 antibody treatment, putting it on track to begin manufacturing the drug once it is authorized by regulators, Regeneron's president said on Tuesday...

UPDATE 5-Regeneron hopes U.S. will authorize coronavirus antibody drug soon

Regeneron Pharmaceuticals Inc said U.S. health regulators were doing a careful analysis of its experimental antibody cocktail to treat COVID-19 and that it was hopeful the drug could be authorized for emergency use in the country soon.

UPDATE 3-Regeneron to stop enrolling very sick COVID-19 patients in antibody trial

Regeneron Pharmaceuticals said on Friday it would stop enrolling patients receiving advanced COVID-19 care in a trial testing its experimental antibody treatment in hospitalized patients, based on the recommendation of an independent safety board.

REFILE-Regeneron to not enrol COVID-19 patients in need of ventilators for antibody trial

Regeneron Pharmaceuticals said on Friday an independent data monitoring panel recommended placing on hold enrolment to its trial for COVID-19 antibody treatment in hospitalized patients requiring high-flow oxygen or mechanical ventilation.

UPDATE 2-Regeneron says its COVID-19 antibody treatment cut medical visits in trial

Regeneron Pharmaceuticals Inc said on Wednesday its coronavirus antibody cocktail - the experimental treatment that U.S. President Donald Trump received - significantly reduced medical visits in a trial of nearly 800 patients with mild-to-moderate COVID-19.

UPDATE 1-Regeneron's drug becomes first FDA-approved Ebola virus treatment

The U.S. Food and Drug Administration on Wednesday approved Regeneron Pharmaceuticals' triple antibody cocktail as the first Ebola virus treatment, lending validation to similar drugs being developed for COVID-19.

U.S. FDA approves Regeneron's drug as first treatment for Ebola virus

The U.S. Food and Drug Administration on Wednesday approved Regeneron Pharmaceuticals' Inmazeb as the first FDA-approved treatment for the Ebola virus infection in adults and children.

CORRECTED-UPDATE 3-U.S. pauses Eli Lilly trial of antibody drug Trump touted as COVID-19 'cure' over safety concern

Eli Lilly and Co said on Tuesday that the government-sponsored clinical trial of its COVID-19 antibody treatment similar to one taken by U.S. President Donald Trump has been paused by the U.S. government because of a safety concern.

UPDATE 2-U.S. expects over 1 mln COVID-19 antibody doses from Regeneron, Lilly in 2020

The U.S. government expects to be able to provide at no cost more than 1 million doses of antibody treatments for COVID-19 similar to the one President Donald Trump received to treat his illness, according to a top U.S. health official on Friday.

HHS expects over 1 mln antibody doses from Regeneron, Lilly in 2020

A top U.S. health official said on Friday that the government expects to have access to over 1 million doses of Regeneron Pharmaceutical Inc's and Eli Lilly's & Co's antibody treatments for COVID-19 in 2020.

UPDATE 1-Regeneron antibodies in demand after Trump treatment, doctors seek more data

Patients are asking to join clinical trials of antibody-based COVID-19 drugs after U.S. President Donald Trump was treated last week with an experimental therapy from Regeneron Pharmaceuticals Inc, and on Wednesday he promised to make it free to Americans while touting its...

Regeneron antibodies in demand after Trump treatment, doctors seek more data

Patients are asking to join clinical trials of antibody-based COVID-19 drugs after U.S. President Donald Trump was treated last week with an experimental therapy from Regeneron Pharmaceuticals Inc, and on Wednesday he promised to make it free to Americans while touting its...

US STOCKS-Wall Street gains with stimulus hopes, positive updates on Trump's health

* Indexes up: Dow 1.3%, S&P 1.4%, Nasdaq 1.8% (Updates to late afternoon)

UPDATE 2-Regeneron says its COVID-19 treatment reduces viral levels, improves symptoms

Regeneron Pharmaceuticals Inc on Tuesday said its experimental two-antibody cocktail reduced viral levels and improved symptoms in non-hospitalized COVID-19 patients, enhancing its chances of becoming a treatment for the disease that has killed over a million people worldwide...

UPDATE 1-Novartis aims to expand Beovu use after safety fears hurt launch

Novartis's Beovu matched Regeneron's Eylea in vision clarity scores for a blindness-causing eye disease, the Swiss drugmaker said on Monday, after early safety stumbles for the medicine in another condition caused disappointing early sales.

Regeneron's antibody drug added to UK Recovery trial of COVID treatments

The world's largest randomised trial of potential medicines for COVID-19 is to add Regeneron's experimental antiviral antibody cocktail REGN-COV2 to the drugs it is testing in patients hospitalised with the disease.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up